Might patients with immune-related diseases benefit from probiotics?

Nutrition

Volumn 29, Issue 3, 2013, Pages 583-586

  Homayouni Rad, Aziz ^a   Torab, Reza ^b   Ghalibaf, Morad ^c   Norouzi, Sharareh ^a   Mehrabany, Elnaz Vaghef ^d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ALLERGIC DISEASE; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BACILLUS COAGULANS; BACTERIAL STRAIN; BIFIDOBACTERIUM BIFIDUM; CLINICAL FEATURE; CROHN DISEASE; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESPONSE; EDITORIAL; ENTERITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; NONHUMAN; PATIENT ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AUTOIMMUNE DISEASES; HUMANS; HYPERSENSITIVITY; IMMUNE SYSTEM DISEASES; PROBIOTICS;

EID: 84873557431     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2012.10.008     Document Type: Editorial

References (52)

1. Ejtahed H.S., Mohtadi-Nia J., Homayouni-Rad A., Niafar M., Asghari-Jafarabadi M., Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition 2012, 28(5):539-543.
2. Water J.V., Naiyanetr P. Yogurt and immunity: The health benefits of fermented milk products that contain lactic acid bacteria. Handbook of fermented functional foods 2003, 130-155. CRC Press, London. E.R. Farnworth (Ed.).
3. Homayouni A. Letter to the editor. Food Chemistry 2009, 114:1073.
4. Percival M. Choosing a probiotic supplement. Clinic Nutrition Insights 1997, 6:1-4.
5. Delcenserie V., Martel D., Lamoureux M., Amiot J., Boutin Y., Roy D. Immunomodulatory effects of probiotics in the intestinal tract. Current Issues in Molecular Biology 2008, 10(1-2):37-54.
6. Roach S., Tannock G.W. Indigenous bacteria that influence the number of Salmonella typhimurium in the spleen of intravenously challenged mice. Can J Microbiol 1980, 26:408-411.
7. Yamazaki S., Kamimura H., Momose H., Kawashima T., Ueda K. Protective effect of bifidobacterium-monoassociation against lethal activity of Escherichia coli. Bifidobacteria Microflora 1982, 1:55.
8. Parracho H., McCartney A.L., Gibson G.R. Probiotics and prebiotics in infant nutrition. Pro Nutr Soc 2007, 66:405-411.
9. Rattanachaikunsopon P., Phumkhachorn P. Lactic acid bacteria: Their antimicrobial compounds and their uses in food production. Annals of Biological Research 2010, 1:218-228.
10. Abbas A.K., Lichtman A.H. Functions and disorders of the immune system. Basic immunology 2007, Elsevier, Philadelphia. 2nd ed.
11. Gill H.S., Grover S., Batish V.K., Gill P. Immunological effects of probiotics and their significance to human health. Prebiotics and probiotics science and technology 2009, 901-948. Springer, Berlin. D. Charalampopoulos, R.A. Rastall (Eds.).
12. Sepkowitz K.A. AIDS-the first 20 years. N Engl J Med 2001, 344:1764-1772.
13. Piatak M., Saag M.S., Yang L.C., Clark S.J., Kappes J.C., Luk K.C., et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993, 259:1749-1754.
14. Pantaleo G., Demarest J.F., Schacker T., Vaccarezza M., Cohen O.J., Daucher M., et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997, 94:254-258.
15. Brostoff J., Male D., Roth D.B., Roitt I. Immunology 2006, Mosby Elsevier, London. 7th ed.
16. Gill H.S., Guarner F. Probiotics and human health: A clinical perspective. Postgrad Med J 2004, 80:516-526.
17. Suttajit M. Advances in nutrition support for quality of life in HIV+/AIDS. Asia Pac J Clin Nutr 2007, 16(Suppl 1):318-322.
18. Cunningham-Rundles S., Ahrné S., Bengmark S., Johann-Liang R., Marshall F., Metakis L., et al. Probiotics and immune response. Am J Gastroenterol 2000, 95(Suppl 1):S22-S25.
19. Trois L., Cardoso E.M., Miura E. Use of probiotics in HIV-infected children: A randomized double-blind controlled study. J Trop Pediatr 2008, 54:19-24.
20. Anukam K.C., Osazuwa E.O., Osadolor H.B., Bruce A.W., Reid G. Yogurt containing probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 helps resolve moderate diarrhea and increases CD4 count in HIV/AIDS patients. J Clin Gastroenterol 2008, 42:239-243.
21. Irvine S.L., Hummelen R., Hekmat S. Probiotic yogurt consumption may improve gastrointestinal symptoms, productivity, and nutritional intake of people living with human immunodeficiency virus in Mwanza, Tanzania. Nutrition Research 2011, 31:875-881.
22. Matsumoto S., Hara T., Hori T., Mitsuyama K., Nagaoka M., Tomiyasu N., et al. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 2005, 140:417-426.
23. Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K.M., Brigidi P., et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology 2003, 124:1202-1209.
24. Gionchetti P., Rizzello F., Venturi A., Campieri M. Probiotics in infective diarrhoea and inflammatory bowel diseases. J Gastroenterol Hepatol 2000, 15:489-493.
25. Kuisma J., Mentula S., Jarvinen H., Kahri A., Saxelin M., Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003, 17:509-515.
26. Gosselink M.P., Schouten W.R., van Lieshout L.M., Hop W.C., Laman J.D., Ruseler-van Embden J.G. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004, 47:876-884.
27. Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot I.C., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004, 53:108-114.
28. Kruis W., Fric P., Pokrotnieks J., Lukás M., Fixa B., Kascák M., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53:1617-1623.
29. Zocco M.A., dal Verme L.Z., Cremonini F., Piscaglia A.C., Nista E.C., Candelli M., et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006, 23:1567-1574.
30. Sood A., Midha V., Makharia G.K., Ahuja V., Singal D., Goswami P., et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatolo 2009, 7:1202-1209.
31. Miele E., Pascarella F., Giannetti E., Quaglietta L., Baldassano R.N., Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. AmJ Gastroenterol 2009, 104:437-443.
32. Tursi A., Brandimarte G., Papa A., Giglio A., Elisei W., Giorgetti G.M., et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010, 105:2218-2227.
33. Matthes H., Krummenerl T., Giensch M., Wolff C., Schulze J. Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010, 10:1-8.
34. Oliva S., Di Nardo G., Ferrari F., Mallardo S., Rossi P., Patrizi G., et al. Randomised clinical trial: The effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 2012, 35:327-334.
35. Gupta P., Andrew H., Kirschner B.S., Guandalini S. Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000, 31:453-457.
36. Guslandi M., Mezzi G., Sorghi M., Testoni P.A. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000, 45:1462-1464.
37. Prantera C., Scribano M.L., Falasco G., Andreoli A., Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A randomised controlled trial with Lactobacillus GG. Gut 2002, 51:405-409.
38. Schultz M., Timmer A., Herfarth H.H., Sartor R.B., Vanderhoof J.A., Rath H.C. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004, 4:5.
39. Bousvaros A., Guandalini S., Baldassano R.N., Botelho C., Evans J., Ferry G.D., et al. A Randomized, Double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005, 11:833-839.
40. Marteau P., Lémann M., Seksik P., Laharie D., Colombel J.F., Bouhnik Y., et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: A randomised, double blind, placebo controlled GETAID trial. Gut 2006, 55:842-847.
41. Van Gossum A., Dewit O., Louis E., de Hertogh G., Baert F., Fontaine F., et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamma Bowel Dis 2007, 13:135-142.
42. Hatakka K., Martio J., Korpela M., Herranen M., Poussa T., Leasanen T., et al. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis-A pilot study. Scand J Rheumatol 2003, 32:211-215.
43. Mandel D.R., Eichas K., Holmes J. Bacillus coagulans: A viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med 2010, 10:1-7.
44. Pineda Mde L., Thompson S.F., Summers K., de Leon F., Pope J., Reid G. A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. Med Sci Monit 2011, 17:CR347-CR354.
45. Pawankar R, Canonica GW, Holgate ST, Lockey RF. WAO white book on allergy 2011-2012: Executive Summary. Accessed August 2, 2012. http://www.worldallergy.org/publications/wao_white_book.pdf.
46. Ghadimi D., lster-Holst R.F., de Vrese M., Winkler P., Heller K.J., Schrezenmeir J. Effects of probiotic bacteria and their genomic DNA on TH1/TH2-cytokine production by peripheral blood mononuclear cells (PBMCs) of healthy and allergic subjects. Immunology 2008, 213:677-692.
47. Dugas B., Mercenier A., Lenoir-Wijnkoop I., Arnaud C., Dugas N., Postaire E. Immunity and probiotics. Immunol Today 1999, 20:387-390.
48. Majamaa H., Isolauri E., Saxelin M., Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1995, 20:333-338.
49. Rosenfeldt V., Benfeldt E., Nielsen S.D., Michaelsen K.F., Jeppesen D.L., Valerius N.H., et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003, 111:389-395.
50. Taylor A.L., Dunstan J.A., Prescott S.L. Probiotic supplementation for the first 6 mo of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: A randomized controlled trial. J Allergy Clin Immunol 2007, 119:184-191.
51. Pohjavuori E., Viljanen M., Korpela R., Kuitunen M., Tiittanen M., Vaarala O., et al. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow's milk allergy. J Allergy Clin Immunol 2004, 114:131-136.
52. Martínez-Cañavate A., Sierra S., Lara-Villoslada F., Romero J., Maldonado J., Boza J., et al. A probiotic dairy product containing L. gasseri CECT5714 and L. coryniformis CECT5711 induces immunological changes in children suffering from allergy. Pediatr Allergy Immunol 2009, 20:592-600.